Rates of Renal, Thyroid Carcinomas Increasing in Children, Adolescents

Article

Results of a new study show that cancer rates among children and adolescents are stable, but rates of certain cancers such as renal carcinomas are increasing.

Results of a new study show that overall cancer rates among children and adolescents are stable, but that the incidence of certain cancers, including renal and thyroid carcinomas, are increasing.

“These findings highlight an opportunity to improve our knowledge of the driving factors of these cancer incidence rate trends, and this understanding may help develop new preventive measures,” wrote David A. Siegel, MD, MPH, of Emory University School of Medicine, and colleagues in Pediatrics.

Siegel and colleagues analyzed data taken from the National Program of Cancer Registries (NPCR) and Surveillance, Epidemiology, and End Results (SEER) registries to identified cancer diagnosed in patients aged 0 to 19 years between 2001 and 2009. According to the study, these registries represent 94.2% of the US population.

Using these registries, they identified 120,137 cases of cancer, with an age-adjusted incidence rate of 171.01 per million. Data showed that the incidence of cancer was higher in boys compared with girls, in adolescents compared with children, and in white children compared with black children. The most commonly occurring cancers were leukemia, followed by central nervous system neoplasms, and lymphomas.

The researchers found no significant change in the cancer incidence from 2001 to 2009 (annual percent change [APC], 0.3%; 95% CI, -0.1 to 0.7). However, they did find that the incidence of thyroid carcinoma (APC, 4.9%; 95% CI, 3.2 to 6.6) and renal carcinoma (APC, 5.4%; 95% CI, 2.8 to 8.1) had increased significantly.

“Rates of renal carcinomas, thyroid carcinomas, and other unspecified malignant neoplasms increased significantly for boys, and the trend for thyroid carcinoma increased significantly for girls,” the researchers wrote. “Increased rate of obesity among adolescents might explain increases in renal carcinomas observed overall and among those aged 15 to 19 years.”

In addition to the results about thyroid and renal carcinoma, the study also found an increasing trend in the overall cancer incidence among black children and adolescents (APC, 1.3%; 95% CI, 0.2 to 2.5). A significant decrease in melanoma was seen overall, as well as in boys, white patients, non-Hispanic patients, adolescents aged 15 to 19 years, and in the Northwest and West regions.

“It is possible that pediatric melanoma is decreasing after an increase seen at the end of the last century,” the researchers wrote. “However, melanoma is often an outpatient disease that adds registry data late into SEER and NPCR.”

Recent Videos
Findings may help providers and patients with head and neck cancer consider whether to proceed with radiotherapy modalities, such as proton therapy or IMRT.
Study results appear to affirm anecdotal information from patients with head and neck cancer related to taste changes during and after radiotherapy.
Noah S. Kalman, MD, MBA, describes the rationale for using a test to measure granular details of taste change in patients undergoing radiotherapy for HNC.
A review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.
A phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
Analysis of 2 phase 1 trials compared gut biome diversity between standard of care with or without CBM588 in patients with metastatic renal cell carcinoma.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Related Content